tiprankstipranks
Aprea Therapeutics Secures Funding and Advances Drug Pipeline
Company Announcements

Aprea Therapeutics Secures Funding and Advances Drug Pipeline

Don't Miss Our Christmas Offers:

Aprea Therapeutics Inc (APRE) has issued an announcement.

Aprea Therapeutics, Inc. has struck a deal with investors for a significant financial boost, agreeing to sell over 1.6 million shares and various tranches of warrants, potentially raking in gross proceeds of around $16 million initially and possibly an additional $18 million in the future. This transaction, set to close on March 13, 2024, hinges on standard closing conditions. The company is also ensuring the resale of these securities by filing the necessary registration statements. In a related move, Aprea terminated a previous sales agreement and announced FDA clearance for a new drug, signaling strategic shifts and progress in its pipeline.

For a thorough assessment of APRE stock, go to TipRanks’ Stock Analysis page.

Related Articles
TheFlyAprea Therapeutics announces first patient dosed in ABOYA-119 Phase 1/2a trial
TheFlyAprea Therapeutics reports Q3 EPS (64c) vs (86c) last year
TipRanks Auto-Generated NewsdeskAprea Therapeutics Reports Promising Results for APR-1051 Trials
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App